These new recommendations were originally provided for immediate use and were later integrated into the website on Maas part of Version 7.0.0.
#Real authentic ms dos 6.22 download update
This update has been endorsed by the Society for Healthcare Epidemiology of America and the Pediatric Infectious Diseases Society. Two new recommendations were developed on the use of lopinavir/ritonavir (prophylaxis for persons exposed to SARS-CoV-2 treatment for ambulatory patients with mild-to-moderate COVID-19).
Version 7.0.0 has been released and includes new recommendations on the use of lopinavir/ritonavir for individuals exposed to or with COVID-19, a revised recommendation on the use of convalescent plasma in ambulatory patients with mild-to-moderate COVID-19, and a revised recommendation for the use of remdesivir in patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk of progression to severe disease. This new recommendation was originally provided for immediate use and was later integrated into the website on Maas part of Version 8.0.0. March 11, 2022Ī new recommendation was developed on the use of bebtelovimab in ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease. Version 7.0.1 has been released and includes an update to the dosing for tixagevimab/cilgavimab as pre-exposure prophylaxis for moderately or severely immunocompromised individuals at increased risk for inadequate immune response to COVID-19 vaccine OR for whom COVID-19 vaccine is not recommended due to a documented serious adverse reaction to the vaccine. Medical Education Community of Practiceĭownload Cite Update History March 18, 2022Ī new recommendation was developed on the use of inhaled corticosteroids in ambulatory patients with mild-to-moderate COVID-19.Fellows-In-Training Career & Education Center.myIDSA Practice Managers Community Opt-in Form.Antimicrobial Stewardship Centers of Excellence Program.